Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine.
We conducted a double-blind study comparing two dosage regimens of a prokinetic drug, cisapride (10 mg q.d.s. and 20 mg b.d.), with a low dose of a H2-receptor antagonist (150 mg ranitidine b.d.) in the treatment of 155 patients with reflux oesophagitis as determined by endoscopy. The active treatment took 8 to 12 weeks depending on whether complete healing was found at endoscopy. Improvement in oesophagitis grades from baseline to endpoint was observed in 68% of patients in the 10 mg cisapride q.d.s. group, 83% in the cisapride 20 mg b.d. group and 81% in the ranitidine group (N.S.). At endpoint, the percentages of endoscopically cured patients with initial grades I or II were 52% for 10 mg cisapride q.d.s., 71% for 20 mg cisapride b.d. and 80% for ranitidine (N.S.). The proportional improvement of the overall reflux symptom score (60%) also showed no significant difference between the three groups. In the treatment of mild reflux oesophagitis (grades I and II) similar results can be expected from 20 mg cisapride b.d. and 150 mg ranitidine b.d. As the results of the two dosage regimens of cisapride were not different, the 20 mg twice daily regimen is preferred because it will improve patient compliance. It is concluded that in reflux oesophagitis grades I and II, the efficacy of 20 mg cisapride b.d. and 150 mg ranitidine b.d. are broadly similar.
Geldof
H
H
Department of Internal Medicine, Ijsselland Hospital, Rotterdam, The Netherlands.
Hazelhoff
B
B
Otten
M H
MH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D020117:Cisapride; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004415:Dyspepsia / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D004945:Esophagoscopy; D006801:Humans; D008276:Magnesium Hydroxide / Q000627:therapeutic use; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects; D011899:Ranitidine / Q000008:administration & dosage* / Q000009:adverse effects; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D016037:Single-Blind Method
D000863:Antacids; D004338:Drug Combinations; D010880:Piperidines; D012702:Serotonin Antagonists; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; D011899:Ranitidine; D008276:Magnesium Hydroxide; D020117:Cisapride